Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study will examine the safety and effectiveness of using lithium, which has been used to
enhance the effectiveness of high-dose 131I, with a single low dose (30 mCi) of 131I for
thyroid ablation in patients with recently diagnosed papillary or follicular thyroid cancer
who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid.
Participants are randomly assigned to receive lithium capsules or placebo (look-alike
capsules with no active ingredient). They follow a low-iodine diet for 2 weeks before
starting treatment and are then admitted to the NIH Clinical Center for study and treatment
for 11 days, during which they remain on the low-iodine diet. Blood samples are collected
almost every day to analyze thyroid hormones, kidney and liver function, lithium
concentrations and other tests.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)